according to the decision of the CPC central Committee and the State Council, the national medical insurance bureau, together with the Ministry of human resources and social security and other departments, organized and carried out the adjustment of the national drug list of basic medical insurance, industrial injury insurance and maternity insurance in 222, which has been successfully concluded. In this adjustment, * * * 111 drugs were added to the catalogue, and 3 drugs were transferred out of the catalogue. Judging from the negotiation and bidding, 147 drugs out of the catalogue participated in the negotiation and bidding (including the renewal negotiation of drugs in the original catalogue), and 121 drugs were successful in negotiation or bidding, with an overall success rate of 82.3%. The average price of newly admitted drugs dropped by 6.1% through negotiation and bidding. After this round of adjustment, the total number of drugs in the national medical insurance drug list reached 2967, including 1586 kinds of western medicine and 1381 kinds of Chinese patent medicine; There are still 892 kinds of Chinese herbal pieces without adjustment. In this adjustment, on the basis of strengthening research and argumentation and soliciting opinions extensively, the National Medical Insurance Bureau introduced bidding mechanism, improved contract renewal rules and optimized evaluation procedures, and the scientific, normative and refined level of catalogue adjustment reached a new level. In the adjustment, the National Medical Insurance Bureau firmly grasps the functional orientation of "ensuring basics", regards the fund affordability as the "bottom line" that must be adhered to, and tries its best to meet the basic drug demand of the majority of insured people; Keep a close eye on the overall situation of national COVID-19 epidemic prevention and control, include qualified COVID-19 therapeutic drugs in the catalogue, and help the epidemic prevention and control with practical actions; Introduce varieties with higher clinical value and cost performance, and successfully upgrade drug security. At the same time, on the basis of ensuring the safety of the fund, this adjustment continues to appropriately relax the payment scope of some varieties in the catalogue, and the accessibility of drugs and the fairness of drug use have been further improved. Since the establishment of the National Medical Insurance Bureau, the drug list has been adjusted for five consecutive years, and a total of 618 drugs have been added to the list. At the same time, a number of drugs with uncertain efficacy, easy clinical abuse or elimination have been transferred out of the list, leading to profound changes in drug users. The Blue Book on the Progress and Effectiveness of Medical Insurance Drug Management Reform in China issued by China Pharmaceutical Association shows that since 218, the proportion of medical insurance drugs used in medical institutions has increased year by year, and the dominant position has been further consolidated, and the rationality of clinical drug use has been actively improved. At the same time, the speed of innovative drugs entering medical insurance has been significantly accelerated, the price level of commonly used drugs has dropped significantly, and the level of drug protection for major diseases and special populations has been greatly improved, which has significantly reduced the drug burden of the people. In the next step, the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security will conscientiously implement the spirit of the 2th National Congress of the Communist Party of China, work hard and bravely forward, pay close attention to the implementation of the new catalogue, and strive to improve the level of drug use protection for the broad masses of the people. At the same time, we will do a good job in guiding the price of therapeutic drugs and ensuring medical expenses in Covid-19, so as to help prevent and control the epidemic situation and build a healthy China with practical actions.

Notice of the Ministry of Human Resources and Social Security of the National Medical Insurance Bureau on Printing and Distributing the National Drug List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (222)

Medical Insurance Fa [223] No.5 Medical Insurance Bureaus and Human Resources and Social Security Bureaus of all provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps: In order to implement the decision-making arrangements of the CPC Central Committee and the State Council, further improve the number of insured persons. In accordance with the requirements of the Interim Measures for the Administration of Medication in Basic Medical Insurance and the Work Plan for the Adjustment of the Drug List of National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance in 222, the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security organized the adjustment and formulation of the Drug List of National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (222) (hereinafter referred to as the Drug List in 222), which is hereby issued, please follow it. The relevant matters are hereby notified as follows: 1. Adjust the scope of payment in time. The 222 Drug Catalogue contains 2,967 kinds of western medicines and Chinese patent medicines, including 1,586 kinds of western medicines and 1,381 kinds of Chinese patent medicines. In addition, there are 892 kinds of Chinese herbal pieces that can be paid by the fund. All localities should strictly implement the Drug Catalogue in 222, and may not adjust the drug varieties, remarks and classification of Party A and Party B in the catalogue by themselves. It is necessary to update the information system and database in a timely manner, include the newly added drugs in this adjustment into the scope of fund payment according to regulations, and transfer the drugs out of the scope of fund payment synchronously, and maintain them in the intelligent supervision subsystem in time to strengthen fund supervision. Second, standardize the payment standard During the agreement period, the negotiated drugs (hereinafter referred to as negotiated drugs) and bidding drugs shall implement the national unified medical insurance payment standard, and each co-ordination area shall determine its self-payment ratio and reimbursement ratio according to the fund's affordability. For bidding drugs, if the actual market price exceeds the payment standard, the excess shall be borne by the insured; If the actual market price is lower than the payment standard, it shall be shared by the medical insurance fund and the insured according to the actual price. Encourage local medical insurance departments to carry out exploration, give priority to the varieties whose prices are not higher than the payment standard under the generic name of bidding drugs into the scope of designated medical institutions and "dual-channel" pharmacies, support clinical priority use and reduce the burden on patients. During the validity period of the agreement, if the negotiated drugs or competitive drugs have specifications that are not specified in the 222 Drug Catalogue and need to be included in the scope of medical insurance payment, the enterprise shall apply to the National Medical Insurance Bureau, which will determine the payment standard according to the terms of the agreement and implement it nationwide. If there is a drug with the same generic name as the negotiated drug listed during the agreement period, its online price shall not be higher than the medical insurance payment standard of the same specification determined through negotiation. The provincial medical insurance department can adjust the medical insurance payment standard of the drug according to the market competition and the price of the same generic drug. During the agreement period, if the negotiated drugs or competitive drugs are included in the centralized drug procurement organized by the state or government pricing, the provincial medical insurance department may adjust the payment standard of drug medical insurance according to relevant regulations. If the medical insurance payment standard is marked with "*" in the Drug List of 222, the local medical insurance and human resources and social security departments shall not publish their medical insurance payment standards in public channels such as public documents and news propaganda. Third, solidly promote the landing of listed drugs. The List of Drugs in 222 was officially implemented on March 1, 223 (the new medical insurance payment standard for azithromycin tablets and Qingfei Jiedu granules in the negotiated drugs was implemented on April 1, 223). Notice of the State Medical Insurance Bureau and the Ministry of Human Resources and Social Security on Printing and Distributing (No.5 [221] of Medical Insurance) shall be abolished at the same time as of March 1, 223. The centralized drug procurement institutions of all provinces, autonomous regions and municipalities directly under the Central Government shall directly link the negotiated drugs on the provincial centralized drug procurement platform before the end of February 223. The online price of negotiated drugs is not higher than the payment standard. Enterprises participating in the catalogue access bidding, within the validity period of the payment standard, the online price of the bidding drugs is not higher than the quotation when participating in the bidding (specific enterprises, drugs and quotations will be notified separately). Provincial medical insurance departments should improve the standardization and refinement of the management of "dual channels" in accordance with the requirements of Guiding Opinions on Establishing and Perfecting the Management Mechanism of National Medical Insurance Negotiation Drugs (No.28 [221] of Medical Insurance) and Notice on Adapting to the Normalization of National Medical Insurance Negotiation and Continuously Doing a Good Job in the Landing of Negotiated Drugs (No.182 [221] of Medical Insurance Letter). Timely update the scope of drugs included in the "dual channel" and paid separately in this province, and implement it simultaneously with the new catalogue. Encourage all localities to actively explore an effective mode to improve the level of drug supply guarantee for rare diseases through "dual channels". Standardize the access procedures of "dual-channel" pharmacies, and further improve the coverage of "dual-channel" pharmacies in rural areas, remote areas and economically underdeveloped areas. Before December 31, 223, all provinces should rely on the national unified medical insurance information platform electronic prescription center to establish and improve the unified, efficient and standardized prescription circulation mechanism in the province, and realize the electronic circulation of "two channels" prescriptions within the province. Continue to improve the monitoring mechanism for the landing of negotiated drugs, and regularly report to the National Health Insurance Bureau the use and payment of negotiated drugs in the 222 Drug Catalogue as required. Local medical insurance departments shall, jointly with relevant departments, guide designated medical institutions to rationally equip and use drugs in the catalogue, and make reasonable adjustments to their annual total amount in combination with the actual drug use of medical institutions. It is necessary to strengthen the agreement management of designated medical institutions with medical insurance, medical institutions with industrial injury insurance agreements and institutions with industrial injury rehabilitation agreements. It is necessary to incorporate the rational allocation and use of drugs in the 222 Drug List into the agreement, and actively promote the implementation of the new catalogue. Fourth, standardize the management of ethnic medicines, medical institution preparations, and Chinese herbal pieces. Provincial medical insurance departments should, in accordance with the requirements of the Interim Measures for the Administration of Medication in Basic Medical Insurance, improve procedures, refine standards, and make scientific calculations, and include ethnic medicines, medical institution preparations, and Chinese herbal pieces that meet the conditions of clinical necessity, reasonable price, and exact curative effect into the scope of fund payment. Conditional areas can simultaneously determine the medical insurance payment standard. At the same time, establish a dynamic adjustment mechanism to transfer unqualified drugs out of the payment scope in time. During the implementation of the Drug List in 222, major problems will be reported to the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security in a timely manner. Annex: List of Drugs for National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (222) I. Examples II. Western Medicine III. Chinese Patent Medicine IV. Drugs negotiated during the agreement period (including competitive drugs) V. Chinese Herbal Pieces IV. Human Resources and Social Security Department of National Medical Insurance Bureau January 13, 223